Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140029/S058

Restylane Contour

Q-Med AB · Decision date Sep 18, 2026

FDA DECISIONP140029/S058

What did the FDA approve?

FDA records P140029/S058 as a supplement to PMA P140029, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 18, 2026.

FDA approval order statement

approval for updated device labeling, including the addition of a statement regarding how the Restylane Contour is only for distribution to providers that have taken and successfully completed device-specific use training program when used for the correction of temple hollowing in patients over the age of 21.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Sep 18, 2026
FDA change category
Labeling Change - PAS

FDA source record

Regulatory record facts

Identifier
P140029/S058
Regulatory pathway
PMA supplement
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P140029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140029 · Original PMA

    Restylane Refyne, Restylane Defyne

  2. P140029/S058 received

    Application receipt date recorded by FDA.

  3. P140029/S058 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P140029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140029

Product / regulatory recordCompanyPathwayDecision dateSource
Q-Med ABPMA approvalDec 9, 2016FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, S-752 28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records